Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02101021 |
Recruitment Status :
Terminated
First Posted : April 1, 2014
Results First Posted : May 9, 2018
Last Update Posted : February 18, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Pancreatic Ductal Adenocarcinoma | Drug: Momelotinib Drug: Placebo to match momelotinib Drug: Nab-paclitaxel Drug: Gemcitabine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase |
Actual Study Start Date : | June 2, 2014 |
Actual Primary Completion Date : | April 10, 2017 |
Actual Study Completion Date : | April 10, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Momelotinib
Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
|
Drug: Momelotinib
Tablet (s) administered orally once or twice daily
Other Names:
Drug: Nab-paclitaxel Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle Drug: Gemcitabine Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle |
Placebo Comparator: Placebo
Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
|
Drug: Placebo to match momelotinib
Placebo to match momelotinib tablets administered orally once or twice daily Drug: Nab-paclitaxel Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle Drug: Gemcitabine Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle |
- Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events [ Time Frame: Up to 28 Days ]
Dose limiting toxicities were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Dose limiting toxicities referred to toxicities experienced during the first 28 days (Cycle 1) of treatment that were judged to be clinically significant and related to study treatment.
No statistical analysis was planned or performed for this endpoint.
- Randomized Treatment Phase: Overall Survival (OS) [ Time Frame: Baseline up to the Date of Death or Censoring, up to 3 years ]Overall survival was defined as the time interval from first dose date of MMB to death from any cause
- Lead-In Phase: Overall Survival (OS) [ Time Frame: Baseline up to the Date of Death or Censoring, up to 3 years ]Overall survival was defined as the time interval from first dose date of MMB to death from any cause
- Lead-In Phase: Progression-Free Survival (PFS) [ Time Frame: Baseline up to the Date of Event or Censoring, up to 3 years ]Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression is progression based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1. Data from survival, non-progressing participants will be censored at the earliest of the time of initiation of anti-tumor therapy other than the study treatment or the last time that lack of definitive disease progression was objectively documented while on study.
- Lead-In Phase: Overall Response Rate (ORR) [ Time Frame: Baseline up to the Last Tumor Assessment Date, up to 3 years ]The ORR was defined as the proportion of participants who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR) as assessed by RECIST v1.1.
- Randomized Treatment Phase: Progression-Free Survival (PFS) [ Time Frame: Baseline up to the Date of Event or Censoring, up to 3 years ]Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause
- Randomized Treatment Phase: Overall Response Rate [ Time Frame: Baseline up to the Last Tumor Assessment Date, up to 3 years ]The ORR was defined as the proportion of subjects who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
-
Presence of metastatic pancreatic adenocarcinoma plus 1 of the following:
- Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically, OR
-
Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin in conjunction with either:
- The presence of a mass in the pancreas, OR
- A history of resected pancreatic adenocarcinoma
- Measurable disease per RECIST v1.1
-
Adequate organ function defined as follows:
- Total bilirubin ≤ 1.25 x upper limit of the normal range (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN
- Absolute neutrophil count (ANC) > 1500 cells/mm^3, platelet > 100,000 cells/mm^3, hemoglobin > 9 g/dL
- Serum creatinine < ULN OR calculated creatinine clearance (CrCl) of ≥ 60 ml/min
- Eastern Cooperative Oncology Group (ECOG ) 0 or 1
- Modified Glasgow prognostic score (mGPS) of 1 or 2 at Screening (randomized phase only)
Key Exclusion Criteria:
- Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy for pancreatic adenocarcinoma
- Currently or previously treated with biologic, small molecule, immunotherapy, chemotherapy, or other agents for metastatic pancreatic carcinoma
- Major surgery within 28 days of first dose of study drug
- Minor surgical procedure(s) within 7 days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ≥ 1 day before enrollment is acceptable)
- Known positive status for HIV
- Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
- Peripheral neuropathy ≥ Grade 2
- Known or suspected brain or central nervous system metastases
- Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinoma
- History of interstitial pneumonitis and/or require supplemental oxygen therapy
- External biliary drain
- Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of enrollment
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02101021
United States, California | |
Cedars-Sinai Medical Center | |
Los Angeles, California, United States, 90048 | |
United States, Indiana | |
Indiana University Health Goshen Center for Cancer Care | |
Goshen, Indiana, United States, 46506 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, Washington | |
Northwest Medical Specialties, PLLC | |
Tacoma, Washington, United States, 98405 |
Study Director: | Gilead Study Director | Gilead Sciences |
Documents provided by Sierra Oncology, Inc.:
Responsible Party: | Sierra Oncology, Inc. |
ClinicalTrials.gov Identifier: | NCT02101021 |
Other Study ID Numbers: |
GS-US-370-1296 2014-004480-20 ( EudraCT Number ) |
First Posted: | April 1, 2014 Key Record Dates |
Results First Posted: | May 9, 2018 |
Last Update Posted: | February 18, 2019 |
Last Verified: | January 2019 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gemcitabine Paclitaxel N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents |
Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Protein Kinase Inhibitors |